BioSpace News Archive

Immunic, Inc. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for patent application 17/391,442, entitled, “Treatment of Multiple Sclerosis Comprising DHODH Inhibitors,” covering a daily dose of about 10 mg to 45 mg of vidofludimus calcium and other salt as well as free acid forms for the treatment of relapsing multiple sclerosis.

DENTSPLY SIRONA Inc. announced that Mr. Brian Gladden has been appointed to its Board of Directors, effective January 1, 2024, to fill the vacancy from Mr. Harry M. Jansen Kraemer, Jr.’s retirement on December 31, 2023.

Cognition Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023 and provided recent business updates.

Intra-Cellular Therapies, Inc. announced its financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Ocugen, Inc. announced that it will host a conference call and live webcast to discuss the Company’s third quarter 2023 financial results and provide a business update at 8:30 a.m. ET on Thursday, November 9, 2023.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, reported its financial results for the third quarter ended September 30, 2023, and provided an update on the Company’s operations.

Arrowhead Pharmaceuticals Inc. announced that it will present new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran and the ARCHES-2 study of zodasiran at the American Heart Association Scientific Sessions 2023, being held in Philadelphia on November 11-13, 2023.

Reneo Pharmaceuticals, Inc. announced that the company’s management team will participate in the following investor conferences.

Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 9, 2023, to review its financial results for the quarter ended September 30, 2023 and to provide a company update.

Theriva™ Biologics and Sant Joan de Déu-Barcelona Children’s Hospital announced that Theriva has executed an exclusive worldwide option to negotiate an exclusive license certain SJD intellectual property rights related to the use of VCN-01 in combination with topoisomerase I inhibitor chemotherapies for the treatment of cancer.